LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it will present new data from a phase 1 safety and pharmacokinetic study of fidaxomicin in children with ...
Probiotic supplements have the potential to prevent diarrhea caused by antibiotics, according to a new Cochrane systematic review. The authors studied Clostridium difficile (C. difficile) infections ...
A Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile associated diarrhea successfully met its primary objective. The top-line results from the recently ...
April 5, 2007 (Munich, Germany) — A database comparison of demographics, risk factors, and hospital outcomes for patients with Clostridium difficile–associated diarrhea (CDAD) shows that the preferred ...
In the final rule concerning Hospital Inpatient Prospective Payment Systems and Fiscal Year 2013, (scheduled for publication in the Federal Register on August 31, 2012), CMS states that: "After ...
Clostridium difficile is the most common cause of nosocomial diarrhea in acute-care settings. Until now, the two available therapies for C. difficile-associated diarrhea (CDAD), vancomycin and ...
Please provide your email address to receive an email when new articles are posted on . Administration of a Saccharomyces boulardii probiotic treatment to hospital patients receiving antibiotics ...
Clostridium difficile-associated disease is receiving renewed attention in medical literature, as the incidence and morbidity from this disease is on the rise. C. difficile-associated disease (CDAD) ...
Background. Since 2002, an epidemic of Clostridium difficile-associated-diarrhea (CDAD) associated with a high case-fatality rate has involved >30 hospitals in the province of Quebec, Canada. In 2003, ...
LAS VEGAS — Potentially deadly antibiotic-associated Clostridium difficile-associated diarrhea (CDAD) affects 3 million Americans each year and is increasingly difficult to treat. Clinicians may want ...
AUSTIN, Texas & TUCSON, Ariz.--(BUSINESS WIRE)--CDISC and The Critical Path Institute (C-Path) are pleased to announce the release of a global Therapeutic Area Standard, which describes how to use ...
Shares of Optimer Pharmaceuticals (NASDAQ:OPTR) rose nearly 7% on Tuesday after the drug maker said its antibacterial diarrhea treatment Dificid was approved by the Food and Drug Administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback